Compliance
FDA’s Center for Drug Evaluation and Research’s (CDER) Office of Compliance
By Mark Land, M.S., RAC, AAHP President The Office of Compliance (OC) shields patients from poor quality, unsafe, and ineffective drugs through compliance strategies and risk-based enforcement actions. OC makes…
Read MoreFDA Office of Compliance Annual Report FY 2022
FDA’s Office of Compliance (OC) recently published its Annual Report for Fiscal Year 2022.1 The report was introduced by Director Jill Furman. Ms. Furman took over the director’s role in…
Read MoreThe HPCUS Friends of the Pharmacopoeia Program
By Dr. William Shevin, President, HPCUS Due to challenges in general for homeopathy and specifically for the Homeopathic Pharmacopoeia Convention of the United States (HPCUS), the standards-setting organization is launching…
Read MoreSummary of FDA’s “Report on the State of Pharmaceutical Quality: Fiscal year 2021”
By Mark Land, M.S., RAC, AAHP President Introduction In August of 2022, the United States Food and Drug Administration (FDA) published its fourth annual Report on the State of Pharmaceutical…
Read MoreWhat’s new at FDA?
The United States Food and Drug Administration is a large organization that changes daily. From the perspective of homeopathic companies, a few important things stand out. FDA published the final…
Read MoreFTC Updates Health Claims Substantiation Guidance
By Alvin J. Lorman, AAHP Legal Counsel In December 2022, the Federal Trade Commission released a lengthy guidance document on the substantiation it expects for health claims, Health Products Compliance…
Read MoreFDA Finalizes Homeopathic Guidance
By Alissa Gould, AAHP Communications Chair Seven years after the U.S. Food and Drug Administration (FDA) held a public hearing on homeopathic product regulation and two rounds of public comments,…
Read MoreFTC Proposes Making Rules Affecting Endorsements and Testimonials
By Alvin Lorman, AAHP Counsel Calling fake and deceptive product reviews and endorsements “problematic” and its remedial authority “limited,” the Federal Trade Commission (FTC) has taken the first step toward…
Read MoreFDA Warning Letters for Skin Tag and Mole Removal OTCs
By Alvin Lorman, AAHP Counsel The Food and Drug Administration (FDA) has reminded two OTC drug manufacturers that mole and skin tag removal are prescription-only indications. The agency issued Warning…
Read MoreThe Legal Status of the HPUS as an Official Compendium
By Al Lorman, AAHP Counsel Pharmacopoeias have been around for thousands of years. Historically, they provided the medical community with critical information necessary to make (and sometimes use) drugs. In…
Read More